Cet anticorps Souris Monoclonal détecte spécifiquement TNFSF11 (Denosumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.
N° du produit ABIN7200656
Aperçu rapide pour Recombinant TNFSF11 (Denosumab Biosimilar) anticorps (ABIN7200656)
Antigène
TNFSF11 (Denosumab Biosimilar)
Type d'anticorp
Recombinant Antibody
Fragment
Fab fragment
Reactivité
Humain
Hôte
Souris
Clonalité
Monoclonal
Conjugué
Cet anticorp TNFSF11 (Denosumab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Classe de qualité
Research Grade
Fonction
Denosumab Biosimilar, Human RANKL Monoclonal Antibody
Specificité
The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.
Attributs du produit
Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.
Purification
Protein A or G affinity column
Pureté
>95 % by reducing SDS-PAGE
Stérilité
0.2 μm filtered
niveau d'endotoxine
< 1 EU per 1 mg of the protein by the LAL method
Immunogène
The monoclonal antibody denosumab biosimilar was produced in the denosumab biosimilar CHO stable cell line.
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.
Restrictions
For Research Use only
Format
Liquid
Concentration
> 3 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Agent conservateur
Without preservative
Stock
4°C,-20 °C
Stockage commentaire
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.